J Liver Cancer.  2025 Mar;25(1):52-66. 10.17998/jlc.2025.02.28.

Management of hepatocellular carcinoma in elderly and adolescent/young adult populations

• Lee HA

• KMID: 2567064
• DOI: http://doi.org/10.17998/jlc.2025.02.28

Abstract

Hepatocellular carcinoma (HCC) presents unique challenges in both the elderly and adolescent/young adult (AYA) populations, requiring distinct management approaches. Recent epidemiological data show an increasing incidence of HCC in both age groups, with elderly cases rising significantly and AYA cases showing trends in specific regions. The clinical characteristics and treatment considerations vary substantially among these populations. Elderly patients with HCC typically present with hepatitis C virus infection, metabolic dysfunction-associated steatotic liver disease, well-differentiated tumors, and multiple comorbidities. In contrast, AYA patients with HCC often present with more aggressive tumor characteristics and predominantly with hepatitis B virus-related diseases. Treatment decisions for elderly patients with HCC require careful consideration of physiological reserves, comprehensive geriatric assessments, and potential complications. Recent studies have demonstrated that elderly patients can achieve outcomes comparable to younger patients across various treatment modalities when properly selected. While surgical outcomes are comparable to those of younger patients with proper selection, less-invasive options such as radiofrequency ablation or transarterial therapies may be more appropriate for some elderly patients. The treatment approach for AYA HCC emphasizes curative intent while considering long-term effects. AYA patients require specialized attention to their psychosocial needs, fertility preservation, and long-term health maintenance. Although data on AYA patients remain limited, they are known to have relatively favorable prognoses despite exhibiting more aggressive tumor characteristics. Management of HCC in both the elderly and AYA populations requires individualized approaches that consider age-specific factors. Both groups benefit from multidisciplinary team involvement and careful consideration of quality of life.

Keyword

Carcinoma, hepatocellular; Aged; Adolescent and young adult; Personalized treatment; Clinical outcome

Reference

References

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68:394–424.

2. Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021; 7:6.

3. Yang JD, Roberts LR. Hepatocellular carcinoma: a global view. Nat Rev Gastroenterol Hepatol. 2010; 7:448–458.

4. Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014; 74:2913–2921.

5. Han J, Wang B, Liu W, Wang S, Chen R, Chen M, et al. Declining disease burden of HCC in the United States, 1992-2017: a population-based analysis. Hepatology. 2022; 76:576–588.

6. Chon YE, Park SY, Hong HP, Son D, Lee J, Yoon E, et al. Hepatocellular carcinoma incidence is decreasing in Korea but increasing in the very elderly. Clin Mol Hepatol. 2023; 29:120–134.

7. Sankar K, Gong J, Osipov A, Miles SA, Kosari K, Nissen NN, et al. Recent advances in the management of hepatocellular carcinoma. Clin Mol Hepatol. 2024; 30:1–15.

8. Lee HA, Lee S, Lee HL, Song JE, Lee DH, Han S, et al. The efficacy of treatment for hepatocellular carcinoma in elderly patients. J Liver Cancer. 2023; 23:362–376.

9. Guan Y, Gan Y, An J. Clinical characteristics and prognosis of early-onset hepatocellular carcinoma: a retrospective cohort study based on population data. Dig Dis Sci. 2024; 69:3563–3573.

10. Korean Liver Cancer Association (KLCA); National Cancer Center (NCC) Korea. 2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma. J Liver Cancer. 2023; 23:1–120.

11. European Association for the Study of the Liver. EASL clinical practice guidelines on the management of hepatocellular carcinoma. J Hepatol. 2025; 82:315–374.

12. Löckenhoff CE, De Fruyt F, Terracciano A, McCrae RR, De Bolle M, Costa PT Jr, et al. Perceptions of aging across 26 cultures and their culturelevel associates. Psychol Aging. 2009; 24:941–954.

13. Seo JH, Kim DH, Cho E, Jun CH, Park SY, Cho SB, et al. Characteristics and outcomes of extreme elderly patients with hepatocellular carcinoma in South Korea. In Vivo. 2019; 33:145–154.

14. National Cancer Institute. All cancer sites combined recent trends in SEER age-adjusted incidence rates, 2000-2021 [Internet]. Rockville (US): National Cancer Institute; [cited 2021 Apr 11]. Available from: https://seer.cancer.gov/explorer/.

15. United States Cancer Statistics. Data visualizations tool technical notes: November, 2018 submission: diagnosis years 1999-2016. Atlanta (US): United States Cancer Statistics; [cited 2024 Dec 1]. Available from: https://www.cdc.gov/united-states-cancer-statistics/technical-notes/pdf/uscs-data-visualizations-tool-technical-notes-2016-508.pdf.

16. Ryerson AB, Eheman CR, Altekruse SF, Ward JW, Jemal A, Sherman RL, et al. Annual report to the nation on the status of cancer, 1975-2012, featuring the increasing incidence of liver cancer. Cancer. 2016; 122:1312–1337.

17. Coccia PF, Pappo AS, Beaupin L, Borges VF, Borinstein SC, Chugh R, et al. Adolescent and young adult oncology, version 2.2018, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2018; 16:66–97.

18. Danpanichkul P, Aboona MB, Sukphutanan B, Kongarin S, Duangsonk K, Ng CH, et al. Incidence of liver cancer in young adults according to the Global Burden of Disease database 2019. Hepatology. 2024; 80:828–843.

19. Wang J, Mao Y, Liu Y, Chen Z, Chen M, Lao X, et al. Hepatocellular carcinoma in children and adolescents: clinical characteristics and treatment. J Gastrointest Surg. 2017; 21:1128–1135.

20. Yu Z, Bai X, Zhou R, Ruan G, Guo M, Han W, et al. Differences in the incidence and mortality of digestive cancer between Global Cancer Observatory 2020 and Global Burden of Disease 2019. Int J Cancer. 2024; 154:615–625.

21. Kim YJ, Jang BK, Kim ES, Chung WJ, Park KS, Cho KB, et al. Hepatocellular carcinoma in the elderly: clinical characteristics, treatment, survival analysis in Korean patients older than 70 years. J Korean Med Sci. 2012; 27:1147–1154.

22. Cho E, Cho HA, Jun CH, Kim HJ, Cho SB, Choi SK. A review of hepatocellular carcinoma in elderly patients focused on management and outcomes. In Vivo. 2019; 33:1411–1420.

23. Yamazaki Y, Kakizaki S, Sohara N, Sato K, Takagi H, Arai H, et al. Hepatocellular carcinoma in young adults: the clinical characteristics, prognosis, and findings of a patient survival analysis. Dig Dis Sci. 2007; 52:1103–1107.

24. Li C, Chen K, Liu X, Liu HT, Liang XM, Liang GL, et al. Analysis of clinicopathological characteristics and prognosis of young patients with hepatocellular carcinoma after hepatectomy. J Clin Transl Hepatol. 2020; 8:285–291.

25. Shen J, Li C, Yan L, Li B, Xu M, Yang J, et al. Short- and long-term outcomes between young and older HCC patients exceeding the Milan criteria after hepatectomy. Ann Hepatol. 2018; 17:134–143.

26. Guo H, Wu T, Lu Q, Dong J, Ren YF, Nan KJ, et al. Hepatocellular carcinoma in elderly: clinical characteristics, treatments and outcomes compared with younger adults. PLoS One. 2017; 12:e0184160.

27. Durand F, Levitsky J, Cauchy F, Gilgenkrantz H, Soubrane O, Francoz C. Age and liver transplantation. J Hepatol. 2019; 70:745–758.

28. Sotaniemi EA, Arranto AJ, Pelkonen O, Pasanen M. Age and cytochrome P450-linked drug metabolism in humans: an analysis of 226 subjects with equal histopathologic conditions. Clin Pharmacol Ther. 1997; 61:331–339.

29. Slawik M, Vidal-Puig AJ. Lipotoxicity, overnutrition and energy metabolism in aging. Ageing Res Rev. 2006; 5:144–164.

30. Petersen KF, Befroy D, Dufour S, Dziura J, Ariyan C, Rothman DL, et al. Mitochondrial dysfunction in the elderly: possible role in insulin resistance. Science. 2003; 300:1140–1142.

31. Ikeda H, Togashi Y. Aging, cancer, and antitumor immunity. Int J Clin Oncol. 2022; 27:316–322.

32. Zhong HH, Hu SJ, Yu B, Jiang SS, Zhang J, Luo D, et al. Apoptosis in the aging liver. Oncotarget. 2017; 8:102640–102652.

33. Chao C, Bhatia S, Xu L, Cannavale KL, Wong FL, Huang PS, et al. Chronic comorbidities among survivors of adolescent and young adult cancer. J Clin Oncol. 2020; 38:3161–3174.

34. Lazow MA, Salloum R, Pressey JG. Comorbidity burden in a cohort of adolescent and young adult patients diagnosed with central nervous system tumors and sarcomas. J Adolesc Young Adult Oncol. 2023; 12:215–223.

35. Kamath PS, Kim WR; Advanced Liver Disease Study Group. The model for end-stage liver disease (MELD). Hepatology. 2007; 45:797–805.

36. Toyoda H, Johnson PJ. The ALBI score: from liver function in patients with HCC to a general measure of liver function. JHEP Rep. 2022; 4:100557.

37. Reig M, Forner A, Rimola J, Ferrer-Fàbrega J, Burrel M, Garcia-Criado Á, et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol. 2022; 76:681–693.

38. Brunot A, Le Sourd S, Pracht M, Edeline J. Hepatocellular carcinoma in elderly patients: challenges and solutions. J Hepatocell Carcinoma. 2016; 3:9–18.

39. Welsh TJ, Gordon AL, Gladman JR. Comprehensive geriatric assessment--a guide for the non-specialist. Int J Clin Pract. 2014; 68:290–293.

40. Singal AG, Llovet JM, Yarchoan M, Mehta N, Heimbach JK, Dawson LA, et al. AASLD practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology. 2023; 78:1922–1965.

41. Nishikawa H, Kimura T, Kita R, Osaki Y. Treatment for hepatocellular carcinoma in elderly patients: a literature review. J Cancer. 2013; 4:635–643.

42. Federico P, Giunta EF, Pappalardo A, Tufo A, Marte G, Attademo L, et al. How to treat hepatocellular carcinoma in elderly patients. Pharmaceuticals (Basel). 2021; 14:233.

43. Garcia EM, Nerurkar SN, Tan EX, Tan SY, Peck EW, Quek SX, et al. Characteristics and outcomes of elderly hepatocellular carcinoma patients following surgical resection: systematic review and meta-analysis. Dig Dis. 2025; 43:206–214.

44. Chu KKW, Chok KSH. Is the treatment outcome of hepatocellular carcinoma inferior in elderly patients? World J Gastroenterol. 2019; 25:3563–3571.

45. Wakabayashi G, Cherqui D, Geller DA, Buell JF, Kaneko H, Han HS, et al. Recommendations for laparoscopic liver resection: a report from the second international consensus conference held in Morioka. Ann Surg. 2015; 261:619–629.

46. Hilal MA, Aldrighetti L, Dagher I, Edwin B, Troisi RI, Alikhanov R, et al. The Southampton Consensus guidelines for laparoscopic liver surgery: from indication to implementation. Ann Surg. 2018; 268:11–18.

47. Dumronggittigule W, Han HS, Ahn S, Yoon YS, Cho JY, Choi Y. Laparoscopic versus open hepatectomy for hepatocellular carcinoma in elderly patients: a single-institutional propensity score matching comparison. Dig Surg. 2020; 37:495–504.

48. Nomi T, Hirokawa F, Kaibori M, Ueno M, Tanaka S, Hokuto D, et al. Laparoscopic versus open liver resection for hepatocellular carcinoma in elderly patients: a multi-centre propensity score-based analysis. Surg Endosc. 2020; 34:658–666.

49. Ahmed FA, Khan SA, Hafeez MS, Jehan FS, Aziz H. Outcomes in elderly patients undergoing hepatic resection compared to ablative therapy for hepatocellular carcinoma. J Surg Oncol. 2023; 128:803–811.

50. Yoo JJ, Koo S, Choi GH, Lee MW, Ryoo S, Park J, et al. Radiofrequency ablation versus surgical resection in elderly hepatocellular carcinoma: a systematic review and meta-analysis. Curr Oncol. 2024; 31:324–334.

51. Conticchio M, Delvecchio A, Ratti F, Gelli M, Anelli FM, Laurent A, et al. Laparoscopic surgery versus radiofrequency ablation for the treatment of single hepatocellular carcinoma ≤3 cm in the elderly: a propensity score matching analysis. HPB (Oxford). 2022; 24:79–86.

52. Hung AK, Guy J. Hepatocellular carcinoma in the elderly: meta-analysis and systematic literature review. World J Gastroenterol. 2015; 21:12197–12210.

53. Fujiwara N, Tateishi R, Kondo M, Minami T, Mikami S, Sato M, et al. Cause-specific mortality associated with aging in patients with hepatocellular carcinoma undergoing percutaneous radiofrequency ablation. Eur J Gastroenterol Hepatol. 2014; 26:1039–1046.

54. Cho SW, Steel J, Tsung A, Marsh JW, Geller DA, Gamblin TC. Safety of liver resection in the elderly: how important is age? Ann Surg Oncol. 2011; 18:1088–1095.

55. Cavagnaro M, Amabile C, Cassarino S, Tosoratti N, Pinto R, Lopresto V. Influence of the target tissue size on the shape of ex vivo microwave ablation zones. Int J Hyperthermia. 2015; 31:48–57.

56. Liang P, Yu J, Lu MD, Dong BW, Yu XL, Zhou XD, et al. Practice guidelines for ultrasound-guided percutaneous microwave ablation for hepatic malignancy. World J Gastroenterol. 2013; 19:5430–5438.

57. Wang Y, Cheng Z, Yu J, Li X, Hao G, Liu F, et al. US-guided percutanous microwave ablation for early-stage hepatocellular carcinoma in elderly patients is as effective as in younger patients: a 10-year experience. J Cancer Res Ther. 2020; 16:292–300.

58. Zhang YX, Zhang XH, Yu XL, Han ZY, Yu J, Liu FY, et al. Prognosis of microwave ablation for hepatocellular carcinoma: does age make a difference? Int J Hyperthermia. 2020; 37:688–695.

59. Luo J, Dong Z, Xie H, Zhang W, An L, Yu Z, et al. Efficacy and safety of percutaneous cryoablation for elderly patients with small hepatocellular carcinoma: a prospective multicenter study. Liver Int. 2022; 42:918–929.

60. Khan SA, Ahmed FA, Hafeez MS, Feng LR, Seth A, Kwon YK, et al. Outcomes in elderly patients undergoing hepatic resection compared to liver transplant for hepatocellular carcinoma. J Surg Oncol. 2023; 128:1320–1328.

61. Cross TJ, Antoniades CG, Muiesan P, Al-Chalabi T, Aluvihare V, Agarwal K, et al. Liver transplantation in patients over 60 and 65 years: an evaluation of long-term outcomes and survival. Liver Transpl. 2007; 13:1382–1388.

62. Schwartz JJ, Pappas L, Thiesset HF, Vargas G, Sorensen JB, Kim RD, et al. Liver transplantation in septuagenarians receiving model for endstage liver disease exception points for hepatocellular carcinoma: the national experience. Liver Transpl. 2012; 18:423–433.

63. Sonny A, Kelly D, Hammel JP, Albeldawi M, Zein N, Cywinski JB. Predictors of poor outcome among older liver transplant recipients. Clin Transplant. 2015; 29:197–203.

64. Sharpton SR, Feng S, Hameed B, Yao F, Lai JC. Combined effects of recipient age and model for end-stage liver disease score on liver transplantation outcomes. Transplantation. 2014; 98:557–562.

65. Garcia CE, Garcia RF, Mayer AD, Neuberger J. Liver transplantation in patients over sixty years of age. Transplantation. 2001; 72:679–684.

66. Gil E, Kim JM, Jeon K, Park H, Kang D, Cho J, et al. Recipient age and mortality after liver transplantation: a population-based cohort study. Transplantation. 2018; 102:2025–2032.

67. Liu PH, Hsu CY, Lee YH, Hsia CY, Huang YH, Su CW, et al. Uncompromised treatment efficacy in elderly patients with hepatocellular carcinoma: a propensity score analysis. Medicine (Baltimore). 2014; 93:e264.

68. Cohen MJ, Bloom AI, Barak O, Klimov A, Nesher T, Shouval D, et al. Trans-arterial chemo-embolization is safe and effective for very elderly patients with hepatocellular carcinoma. World J Gastroenterol. 2013; 19:2521–2528.

69. Salem R, Gordon AC, Mouli S, Hickey R, Kallini J, Gabr A, et al. Y90 radioembolization significantly prolongs time to progression compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology. 2016; 151:1155–1163. e2.

70. Salem R, Johnson GE, Kim E, Riaz A, Bishay V, Boucher E, et al. Yttrium-90 radioembolization for the treatment of solitary, unresectable HCC: the LEGACY study. Hepatology. 2021; 74:2342–2352.

71. Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020; 382:1894–1905.

72. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008; 359:378–390.

73. Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018; 391:1163–1173.

74. Bruix J, Chan SL, Galle PR, Rimassa L, Sangro B. Systemic treatment of hepatocellular carcinoma: an EASL position paper. J Hepatol. 2021; 75:960–974.

75. Tada T, Kumada T, Hiraoka A, Hirooka M, Kariyama K, Tani J, et al. Safety and efficacy of atezolizumab plus bevacizumab in elderly patients with hepatocellular carcinoma: a multicenter analysis. Cancer Med. 2022; 11:3796–3808.

76. Abou-Alfa GK, Lau G, Kudo M, Chan SL, Kelley RK, Furuse J, et al. Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. NEJM Evid. 2022; 1:EVIDoa2100070.

77. Shimose S, Saeki I, Tomonari T, Ito T, Tani J, Takeuchi Y, et al. Initial clinical experience with durvalumab plus tremelimumab in patients with unresectable hepatocellular carcinoma in real-world practice. Oncol Lett. 2024; 28:397.

78. Tada T, Kumada T, Hiraoka A, Michitaka K, Atsukawa M, Hirooka M, et al. Safety and efficacy of lenvatinib in elderly patients with unresectable hepatocellular carcinoma: a multicenter analysis with propensity score matching. Hepatol Res. 2020; 50:75–83.

79. Zebrack B, Mathews-Bradshaw B, Siegel S; LIVESTRONG Young Adult Alliance. Quality cancer care for adolescents and young adults: a position statement. J Clin Oncol. 2010; 28:4862–4867.

80. Bleyer A. Young adult oncology: the patients and their survival challenges. CA Cancer J Clin. 2007; 57:242–255.

81. Vimalesvaran S, Souza LN, Deheragoda M, Samyn M, Day J, Verma A, et al. Outcomes of adults who received liver transplant as young children. EClinicalMedicine. 2021; 38:100987.

82. Bhatia S, Pappo AS, Acquazzino M, Allen-Rhoades WA, Barnett M, Borinstein SC, et al. Adolescent and young adult (AYA) oncology, version 2.2024, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2023; 21:851–880.

83. Ishibashi A, Okamura J, Ueda R, Sunami S, Kobayashi R, Ogawa J. Psychosocial strength enhancing resilience in adolescents and young adults with cancer. J Pediatr Oncol Nurs. 2016; 33:45–54.

84. Morgan S, Davies S, Palmer S, Plaster M. Sex, drugs, and rock 'n' roll: caring for adolescents and young adults with cancer. J Clin Oncol. 2010; 28:4825–4830.

85. Smith AW, Seibel NL, Lewis DR, Albritton KH, Blair DF, Blanke CD, et al. Next steps for adolescent and young adult oncology workshop: an update on progress and recommendations for the future. Cancer. 2016; 122:988–999.

86. Salama M, Isachenko V, Isachenko E, Rahimi G, Mallmann P. Advances in fertility preservation of female patients with hematological malignancies. Expert Rev Hematol. 2017; 10:951–960.

87. Quidde J, von Grundherr J, Koch B, Bokemeyer C, Escherich G, Valentini L, et al. Improved nutrition in adolescents and young adults after childhood cancer - INAYA study. BMC Cancer. 2016; 16:872.

88. Wurz A, Brunet J. Exploring the feasibility and acceptability of a mixed-methods pilot randomized controlled trial testing a 12-week physical activity intervention with adolescent and young adult cancer survivors. Pilot Feasibility Stud. 2019; 5:154.

89. Zeng J, Lin K, Liu H, Huang Y, Guo P, Zeng Y, et al. Prognosis factors of young patients undergoing curative resection for hepatitis B virus-related hepatocellular carcinoma: a multicenter study. Cancer Manag Res. 2020; 12:6597–6606.

90. Commander SJ, Cerullo M, Arjunji N, Leraas HJ, Thornton S, Ravindra K, et al. Improved survival and higher rates of surgical resection associated with hepatocellular carcinoma in children as compared to young adults. Int J Cancer. 2022; 151:2206–2214.

91. Shimada S, Kamiyama T, Yokoo H, Wakayama K, Tsuruga Y, Kakisaka T, et al. Clinicopathological characteristics and prognostic factors in young patients after hepatectomy for hepatocellular carcinoma. World J Surg Oncol. 2013; 11:52.

92. Chang PE, Ong WC, Lui HF, Tan CK. Is the prognosis of young patients with hepatocellular carcinoma poorer than the prognosis of older patients? A comparative analysis of clinical characteristics, prognostic features, and survival outcome. J Gastroenterol. 2008; 43:881–888.

93. Takeishi K, Shirabe K, Muto J, Toshima T, Taketomi A, Maehara Y. Clinicopathological features and outcomes of young patients with hepatocellular carcinoma after hepatectomy. World J Surg. 2011; 35:1063–1071.